OXFBD04 is a potent and selective BRD4 inhibitor with an IC 50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity
In Vitro
OXFBD04 (0.01-100 μM; 48 hours) inhibits cancer cell lines growth. OXFBD04 (10 µM; for 10, 24, or 48 hours) induces MYC suppression in MCF7 breast cancer cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A498 (renal), HT-29 (colon), and MCF7 (breast) cancer cell lines Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time: 48 hours Result: Inhibited cancer cell lines growth.
In Vivo
OXFBD04 has optimised physicochemical properties (LE=0.43; LLE=5.74; SFI=5.96), and good metabolic stability (t 1/2 =388 min). OXFBD04 has CL int of 3.57 µL/min/mg . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:BRD4 166 nM (IC 50 )
Associated Targets
BRD4Tchem Bromodomain-containing protein 4 3 Activities
